307 related articles for article (PubMed ID: 34286438)
1. CXCL3 Signaling in the Tumor Microenvironment.
Reyes N; Figueroa S; Tiwari R; Geliebter J
Adv Exp Med Biol; 2021; 1302():15-24. PubMed ID: 34286438
[TBL] [Abstract][Full Text] [Related]
2. CXCL3: A key player in tumor microenvironment and inflammatory diseases.
Bao Y; Tong C; Xiong X
Life Sci; 2024 Jul; 348():122691. PubMed ID: 38714265
[TBL] [Abstract][Full Text] [Related]
3. Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer.
Song N; Cui K; Zeng L; Li M; Fan Y; Shi P; Wang Z; Su W; Wang H
Eur J Pharmacol; 2024 Mar; 967():176357. PubMed ID: 38309677
[TBL] [Abstract][Full Text] [Related]
4. Exploration of prognostic biomarkers and therapeutic targets in the microenvironment of bladder cancer based on CXC chemokines.
Sun X; Chen Q; Zhang L; Chen J; Zhang X
Math Biosci Eng; 2021 Jul; 18(5):6262-6287. PubMed ID: 34517533
[TBL] [Abstract][Full Text] [Related]
5. The role of CXC chemokines and their receptors in cancer.
Vandercappellen J; Van Damme J; Struyf S
Cancer Lett; 2008 Aug; 267(2):226-44. PubMed ID: 18579287
[TBL] [Abstract][Full Text] [Related]
6. ELR+ CXC chemokines in human milk.
Maheshwari A; Christensen RD; Calhoun DA
Cytokine; 2003 Nov; 24(3):91-102. PubMed ID: 14581003
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical significance of CXC chemokines in the glioblastoma microenvironment.
Li C; Deng H; Zhou Y; Ye Y; Zhao S; Liang S; Cai S; Lin J; Tang Y; Wu Y
Life Sci; 2020 Nov; 261():118486. PubMed ID: 32976881
[TBL] [Abstract][Full Text] [Related]
8. The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis.
Addison CL; Arenberg DA; Morris SB; Xue YY; Burdick MD; Mulligan MS; Iannettoni MD; Strieter RM
Hum Gene Ther; 2000 Jan; 11(2):247-61. PubMed ID: 10680839
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer.
Jing Y; Wang F; Zhang K; Chen Z
BMC Med Genomics; 2022 Apr; 15(1):96. PubMed ID: 35468838
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment signaling and therapeutics in cancer progression.
Goenka A; Khan F; Verma B; Sinha P; Dmello CC; Jogalekar MP; Gangadaran P; Ahn BC
Cancer Commun (Lond); 2023 May; 43(5):525-561. PubMed ID: 37005490
[TBL] [Abstract][Full Text] [Related]
11. CXC chemokines located in the 4q21 region are up-regulated in breast cancer.
Bièche I; Chavey C; Andrieu C; Busson M; Vacher S; Le Corre L; Guinebretière JM; Burlinchon S; Lidereau R; Lazennec G
Endocr Relat Cancer; 2007 Dec; 14(4):1039-52. PubMed ID: 18045955
[TBL] [Abstract][Full Text] [Related]
12. Exploration of potential therapeutic and prognostic value of CXC chemokines in cervical squamous cell carcinoma and endocervical adenocarcinoma based on bioinformatics analysis.
Wu C; Ma C; Yuan J; Zhou P
Math Biosci Eng; 2021 Sep; 18(6):8201-8222. PubMed ID: 34814296
[TBL] [Abstract][Full Text] [Related]
13. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix.
Engl T; Relja B; Blumenberg C; Müller I; Ringel EM; Beecken WD; Jonas D; Blaheta RA
Life Sci; 2006 Mar; 78(16):1784-93. PubMed ID: 16263140
[TBL] [Abstract][Full Text] [Related]
14. Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment.
Zeng Q; Sun S; Li Y; Li X; Li Z; Liang H
Front Oncol; 2019; 9():1555. PubMed ID: 32117786
[No Abstract] [Full Text] [Related]
15. The Inflammatory CXC Chemokines, GROα
Cao Y; Huang H; Wang Z; Zhang G
Immunol Invest; 2017 May; 46(4):361-374. PubMed ID: 28375674
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic values of C‑X‑C motif chemokine ligand 3 in patients with colon cancer.
Ruan GT; Gong YZ; Liao XW; Wang S; Huang W; Wang XK; Zhu GZ; Liao C; Gao F
Oncol Rep; 2019 Nov; 42(5):1996-2008. PubMed ID: 31545503
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors-A Review of Literature.
Korbecki J; Kojder K; Kapczuk P; Kupnicka P; Gawrońska-Szklarz B; Gutowska I; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467722
[TBL] [Abstract][Full Text] [Related]
18. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
Bizzarri C; Beccari AR; Bertini R; Cavicchia MR; Giorgini S; Allegretti M
Pharmacol Ther; 2006 Oct; 112(1):139-49. PubMed ID: 16720046
[TBL] [Abstract][Full Text] [Related]
19. CXC Chemokine Signaling in Progression of Epithelial Ovarian Cancer: Theranostic Perspectives.
Huang X; Hao J; Tan YQ; Zhu T; Pandey V; Lobie PE
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269786
[TBL] [Abstract][Full Text] [Related]
20. CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.
Lee HJ; Song IC; Yun HJ; Jo DY; Kim S
World J Gastroenterol; 2014 Feb; 20(7):1681-93. PubMed ID: 24587647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
